文献速递结核与非结核分枝杆菌

中国耐利福平结核病6-9个月全口服方案随机非劣效试验

A 6- to 9-months oral regimen for rifampicin-resistant tuberculosis: a randomized open-label noninferiority trial in China.
PubMed 文献 · Clin Microbiol Infect · 2025-11-24

在中国开展的开放标签随机非劣效试验中,耐利福平肺结核患者随机接受6-9个月全口服方案或9个月含注射剂方案。改良意向治疗分析显示全口服方案有利结局率76.1%对63.7%,差异12.4%(95%CI 2.4-22.5%),非劣效性p<0.0001。全口服方案可作为无法获得贝达喹啉等药物的替代选择。

要点

  • 全口服方案6-9个月对耐利福平肺结核非劣效于9个月含注射剂方案。
  • 全口服方案3-5级不良事件发生率59.5%,低于对照组的69.1%。
  • QTcF延长发生率全口服组29.5%,对照组44.6%。

核心结论

  • 全口服方案在84周有利结局方面非劣效于9个月含注射剂方案。
  • 全口服方案对最新WHO推荐的含贝达喹啉方案的疗效需进一步验证。

研究设计与样本

  • 开放标签、随机、非劣效性试验,在中国开展。
  • 耐利福平肺结核患者按1:1随机分配至6-9个月全口服方案组或9个月含注射剂对照组。
  • 共660例入组,354例随机化;改良意向治疗分析纳入312例,符合方案分析纳入260例。
  • 主要结局为治疗开始后84周的有利结局,非劣效界值10%。

主要发现

  • 改良意向治疗分析:全口服组76.1%对对照组63.7%获得有利结局,差异12.4%(95%CI 2.4-22.5%),非劣效性p<0.0001。
  • 符合方案分析:全口服组84.4%对对照组73.5%获得有利结局,差异10.9%(95%CI 1.1-20.7%),非劣效性p<0.0001。
  • 3-5级不良事件发生率:对照组69.1%,全口服组59.5%。
  • QTcF延长发生率:对照组44.6%,全口服组29.5%。
  • 肝胆疾病发生率:对照组21.7%,全口服组7.5%。

关键数值与推荐

  • 全口服方案组成:左氧氟沙星、利奈唑胺、环丝氨酸、氯法齐明和/或吡嗪酰胺。
  • 对照方案为9个月含注射剂方案。
  • 主要结局定义:连续两次培养阴性且无先前不利结局。
  • 非劣效界值为10%。

临床怎么用

  • 全口服方案可作为缺乏贝达喹啉、德拉马尼或普托马尼时耐利福平肺结核的替代治疗选择。
  • 全口服方案不良事件(尤其QTcF延长和肝胆疾病)发生率低于含注射剂方案。

局限性

  • 全口服方案对最新WHO推荐的含贝达喹啉方案的疗效需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Despite advancements in shorter, oral regimens for drug-resistant tuberculosis, more options are needed to extent patient benefits. We conducted a trial to evaluate the noninferiority of an all-oral regimen compared with the injectable-containing regimen. METHODS: In an open-label, randomized noninferiority trial in China, participants with rifampicin-resistant pulmonary tuberculosis were assigned 1:1 to a 6- to 9-month all-oral regimen (levofloxacin, linezolid, cycloserine, clofazimine and/or pyrazinamide) and a 9-month injectable-containing control regimen. The primary outcome was a favourable outcome at 84 weeks after treatment initiation, defined by two consecutive, negative cultures with no previous unfavourable outcome, using a noninferiority margin of 10%. RESULTS: Between 2 June 2020, and 1 December 2021, 660 participants were enrolled and 354 underwent randomization. A total of 312 and 260 participants were included in the modified intention-to-treat and the per-protocol analysis, respectively. In the modified intention-to-treat analysis, 76.1% of participants in the oral group and 63.7% of those in the control group had a favourable outcome at 84 weeks (difference, 12.4%; 95% CI, 2.4-22.5%; noninferiority p < 0.0001). In the per-protocol analysis, 84.4% of participants in the oral group and 73.5% of participants in the control group had a favourable outcome (difference, 10.9%; 95% CI, 1.1-20.7%; noninferiority p < 0.0001). Grade 3 to 5 adverse events occurred in 69.1% of participants in the control group and 59.5% in the oral group. The most common grade 3 to 5 adverse events were QTcF (corrected QT interval calculated with Fridericia's formula) prolongation, affecting 44.6% of participants in the control group and 29.5% of participants in the oral group. Hepatobiliary disorder occurred more frequently in the control group (21.7%) compared with the oral group (7.5%). CONCLUSIONS: The all-oral regimen was noninferior to the 9-month injectable-containing regimen, offering an alternative for patients lacking access to bedaquiline, delamanid or pretomanid. However, its efficacy against the latest WHO-recommended bedaquiline-containing regimens requires further validation.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Sun F, Li Y, Zhang Y, et al. A 6- to 9-months oral regimen for rifampicin-resistant tuberculosis: a randomized open-label noninferiority trial in China. Clin Microbiol Infect. 2025. PMID: 41297761. doi:10.1016/j.cmi.2025.11.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。